世界の骨髄異形成症候群(MDS)治療市場 2019年

【英語タイトル】Global Myelodysplastic Syndrome (MDS) Treatment Market Professional Survey Report 2019

QYResearchが出版した調査資料(QYR20FB03200)・商品コード:QYR20FB03200
・発行会社(調査会社):QYResearch
・発行日:2019年10月(※2024年版があります。お問い合わせください)
・ページ数:105
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、骨髄異形成症候群(MDS)治療の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アザシチジン、レナリドミド、デシタビン、デフェラシロクスに、用途別には、単一血球系統の異形成を伴う不応性血球減少症、環状鉄芽球を伴う不応性貧血、その他にセグメント区分し、骨髄異形成症候群(MDS)治療の世界市場を分析しました。


・エグゼクティブ・サマリー
・骨髄異形成症候群(MDS)治療の世界市場概要
・骨髄異形成症候群(MDS)治療の製造コスト構成分析
・骨髄異形成症候群(MDS)治療の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・骨髄異形成症候群(MDS)治療の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・骨髄異形成症候群(MDS)治療のセグメント分析(種類別)
(アザシチジン、レナリドミド、デシタビン、デフェラシロクス)
・骨髄異形成症候群(MDS)治療のセグメント分析(用途別)
(単一血球系統の異形成を伴う不応性血球減少症、環状鉄芽球を伴う不応性貧血、その他)
・骨髄異形成症候群(MDS)治療の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd、Sandoz Inc、Dr Reddys Laboratories Limited、Pharmascience Inc、Accord Healthcare Ltd、Mylan N.V.)
・骨髄異形成症候群(MDS)治療の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.

The global Myelodysplastic Syndrome (MDS) Treatment market was valued at 2210 million US$ in 2018 and will reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025.
This report focuses on Myelodysplastic Syndrome (MDS) Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome (MDS) Treatment market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Myelodysplastic Syndrome (MDS) Treatment in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Myelodysplastic Syndrome (MDS) Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox

Segment by Application
Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Myelodysplastic Syndrome (MDS) Treatment
1.1 Definition of Myelodysplastic Syndrome (MDS) Treatment
1.2 Myelodysplastic Syndrome (MDS) Treatment Segment by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.3 Myelodysplastic Syndrome (MDS) Treatment Segment by Applications
1.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Comparison by Applications (2014-2025)
1.3.2 Refractory cytopenia with unilineage dysplasia
1.3.3 Refractory anemia with ringed sideroblasts
1.3.4 Others
1.4 Global Myelodysplastic Syndrome (MDS) Treatment Overall Market
1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue (2014-2025)
1.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Production (2014-2025)
1.4.3 North America Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.4 Europe Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.5 China Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.6 Japan Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.7 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)
1.4.8 India Myelodysplastic Syndrome (MDS) Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Treatment
2.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment
2.4 Industry Chain Structure of Myelodysplastic Syndrome (MDS) Treatment

3 Development and Manufacturing Plants Analysis of Myelodysplastic Syndrome (MDS) Treatment
3.1 Capacity and Commercial Production Date
3.2 Global Myelodysplastic Syndrome (MDS) Treatment Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Myelodysplastic Syndrome (MDS) Treatment
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Myelodysplastic Syndrome (MDS) Treatment Production and Capacity Analysis
4.2 Myelodysplastic Syndrome (MDS) Treatment Revenue Analysis
4.3 Myelodysplastic Syndrome (MDS) Treatment Price Analysis
4.4 Market Concentration Degree

5 Myelodysplastic Syndrome (MDS) Treatment Regional Market Analysis
5.1 Myelodysplastic Syndrome (MDS) Treatment Production by Regions
5.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Production by Regions
5.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions
5.2 Myelodysplastic Syndrome (MDS) Treatment Consumption by Regions
5.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Production
5.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.4 Europe Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.4.1 Europe Myelodysplastic Syndrome (MDS) Treatment Production
5.4.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.5 China Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.5.1 China Myelodysplastic Syndrome (MDS) Treatment Production
5.5.2 China Myelodysplastic Syndrome (MDS) Treatment Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.6 Japan Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.6.1 Japan Myelodysplastic Syndrome (MDS) Treatment Production
5.6.2 Japan Myelodysplastic Syndrome (MDS) Treatment Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.7 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.7.1 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Production
5.7.2 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Import and Export
5.8 India Myelodysplastic Syndrome (MDS) Treatment Market Analysis
5.8.1 India Myelodysplastic Syndrome (MDS) Treatment Production
5.8.2 India Myelodysplastic Syndrome (MDS) Treatment Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Myelodysplastic Syndrome (MDS) Treatment Import and Export

6 Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Type)
6.1 Global Myelodysplastic Syndrome (MDS) Treatment Production by Type
6.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type
6.3 Myelodysplastic Syndrome (MDS) Treatment Price by Type

7 Myelodysplastic Syndrome (MDS) Treatment Segment Market Analysis (by Application)
7.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption by Application
7.2 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Market Share by Application (2014-2019)

8 Myelodysplastic Syndrome (MDS) Treatment Major Manufacturers Analysis
8.1 Novartis AG
8.1.1 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.1.2 Novartis AG Product Introduction, Application and Specification
8.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Celgene Corporation
8.2.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.2.2 Celgene Corporation Product Introduction, Application and Specification
8.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Otsuka Pharmaceutical Co., Ltd
8.3.1 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.3.2 Otsuka Pharmaceutical Co., Ltd Product Introduction, Application and Specification
8.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Sandoz Inc
8.4.1 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.4.2 Sandoz Inc Product Introduction, Application and Specification
8.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Dr Reddys Laboratories Limited
8.5.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.5.2 Dr Reddys Laboratories Limited Product Introduction, Application and Specification
8.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Pharmascience Inc
8.6.1 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.6.2 Pharmascience Inc Product Introduction, Application and Specification
8.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Accord Healthcare Ltd
8.7.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.7.2 Accord Healthcare Ltd Product Introduction, Application and Specification
8.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Mylan N.V.
8.8.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
8.8.2 Mylan N.V. Product Introduction, Application and Specification
8.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served

9 Development Trend of Analysis of Myelodysplastic Syndrome (MDS) Treatment Market
9.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Trend Analysis
9.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size (Volume and Value) Forecast 2019-2025
9.2 Myelodysplastic Syndrome (MDS) Treatment Regional Market Trend
9.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.3 China Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.4 Japan Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.5 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.2.6 India Myelodysplastic Syndrome (MDS) Treatment Forecast 2019-2025
9.3 Myelodysplastic Syndrome (MDS) Treatment Market Trend (Product Type)
9.4 Myelodysplastic Syndrome (MDS) Treatment Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Myelodysplastic Syndrome (MDS) Treatment Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer



【掲載企業】

Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd、Sandoz Inc、Dr Reddys Laboratories Limited、Pharmascience Inc、Accord Healthcare Ltd、Mylan N.V.

★調査レポート[世界の骨髄異形成症候群(MDS)治療市場 2019年] (コード:QYR20FB03200)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の骨髄異形成症候群(MDS)治療市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆